A phase i trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancer

A. A. Chiappori, M. T. Schreeder, M. M. Moezi, J. J. Stephenson, J. Blakely, R. Salgia, Q. S. Chu, H. J. Ross, D. S. Subramaniam, J. Schnyder, M. S. Berger

Research output: Contribution to journalArticlepeer-review

39 Scopus citations

Fingerprint Dive into the research topics of 'A phase i trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences